SymBio and Eisai develop bendamustine in Japan
This article was originally published in Scrip
Executive Summary
Eisaiis to develop and commercialiseSymBio Pharmaceuticals's anticancer bendamustine in Japan, in an agreement worth up to ¥4.0 billion ($36.3 million) in up-front and development milestone payments to the Japanese venture.